Most cited papers from Eisai (United States)

Eisai (United States)

What are the most cited papers from Eisai (United States)?

The most cited paper from Eisai (United States) is "Lecanemab in Early Alzheimer’s Disease" (Christopher H. van Dyck, Chad J. Swanson, Paul S. S. Aisen et al., 2022), with 5,691 citations. Next come "Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial" (5,578) and "Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer" (2,109).

Published TypeFieldAccessAuthorsCitations

Showing 50 of 61 papers. Every paper with more than 285 citations is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	Lecanemab in Early Alzheimer’s Disease Christopher H. van Dyck, Chad J. Swanson, Paul S. S. Aisen et al. · New England Journal of Medicine Open access	30 Nov 2022	5,691
2	Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial Masatoshi Kudo et al. · The Lancet Open access	Mar 2018	5,578
3	Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer Martin Jean Schlumberger, Makoto Tahara, Lori J. Wirth et al. · New England Journal of Medicine Open access	11 Feb 2015	2,109
4	Toll-like Receptor-4 Mediates Lipopolysaccharide-induced Signal Transduction Jesse C. Chow, Donna W. Young, Douglas Taylor Golenbock et al. · Journal of Biological Chemistry Open access	Apr 1999	1,974
5	The Amyloid-β Pathway in Alzheimer’s Disease Harald Juergen Hampel, John Hardy, Kaj Blennow et al. · Molecular Psychiatry Open access	29 Aug 2021	1,929
6	Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma Robert John Motzer et al. · New England Journal of Medicine Open access	13 Feb 2021	1,811
7	The Extra Domain A of Fibronectin Activates Toll-like Receptor 4 Yoshinori Okamura, Michiko Watari, Elliot S. Jerud et al. · Journal of Biological Chemistry Open access	Mar 2001	1,224
8	Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma Richard S. Finn, Masafumi Ikeda, Andrew Xiuxuan Zhu et al. · Journal of Clinical Oncology Open access	27 Jul 2020	1,188
9	Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study Javier Cortés, Joyce O’Shaughnessy, David M. Loesch et al. · The Lancet	Mar 2011	1,110
10	mRNA Is an Endogenous Ligand for Toll-like Receptor 3 Katalin Karikó, Houping Ni, John Capodici et al. · Journal of Biological Chemistry Open access	Mar 2004	1,061
11	Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial Robert John Motzer, Thomas E. Hutson, Hilary Glen et al. · The Lancet Oncology Open access	25 Oct 2015	957
12	A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody Chad J. Swanson, Yong Zhang, Shobha Dhadda et al. · Alzheimer s Research & Therapy Open access	17 Apr 2021	844
13	Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial Patrick Schöffski, Sant P. Chawla, Robert G. Maki et al. · The Lancet Open access	12 Feb 2016	782
14	The Efficacy and Safety of Donepezil in Patients with Alzheimer's Disease: Results of a US Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial Sharon L. Rogers, Lawrence T. Friedhoff · Dementia and Geriatric Cognitive Disorders	1996	743
15	The β-Secretase BACE1 in Alzheimer’s Disease Harald Juergen Hampel et al. · Biological Psychiatry Open access	12 Feb 2020	695
16	The odyssey of marine pharmaceuticals: a current pipeline perspective Alejandro M. S. Mayer, Keith B. Glaser, Carmen Cuevas et al. · Trends in Pharmacological Sciences	6 Apr 2010	669
17	Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study Antoîne Italiano, Jean‐Charles Soria, Maud Toulmonde et al. · The Lancet Oncology	9 Apr 2018	633
18	Alzheimer’s Disease: Epidemiology and Clinical Progression Amir Abbas Tahami Monfared, Michael J. Byrnes, Leigh Ann White et al. · Neurology and Therapy Open access	14 Mar 2022	619
19	The Effects of Donepezil in Alzheimer’s Disease – Results from a Multinational Trial1 Alistair S. Burns, Martin N. Rossor, Jane Hecker et al. · Dementia and Geriatric Cognitive Disorders Open access	1999	587
20	Malaria hemozoin is immunologically inert but radically enhances innate responses by presenting malaria DNA to Toll-like receptor 9 Peggy Parroche, Fanny N. Lauw, Nadège Goutagny et al. · Proceedings of the National Academy of Sciences Open access	2 Feb 2007	575
21	Reporting guidelines for human microbiome research: the STORMS checklist Chloe A. Mirzayi et al. · Nature Medicine Open access106 authors	Nov 2021	540
22	H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers Michael Seiler et al. · Nature Medicine Open access	19 Feb 2018	533
23	Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer Vicky Makker, Matthew Hiram Taylor, Carol A Aghajanian et al. · Journal of Clinical Oncology Open access	13 Mar 2020	531
24	Lenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage Yuji Yamamoto et al. · Vascular Cell Open access	2014	506
25	Antitumor Activity of Lenvatinib (E7080): An Angiogenesis Inhibitor That Targets Multiple Receptor Tyrosine Kinases in Preclinical Human Thyroid Cancer Models Osamu Tohyama, Junji Matsui, Kotaro Kodama et al. · Journal of Thyroid Research Open access	2014	483
26	Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial Vicky Makker, Drew Warren Rasco, Nicholas J. Vogelzang et al. · The Lancet Oncology Open access	26 Mar 2019	482
27	Cancer-Associated SF3B1 Hotspot Mutations Induce Cryptic 3′ Splice Site Selection through Use of a Different Branch Point Rachel B. Darman et al. · Cell Reports Open access	25 Oct 2015	475
28	Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway Yu Kato, Kimiyo Tabata, Takayuki Kimura et al. · PLoS ONE Open access	27 Feb 2019	471
29	Ligand-induced conformational changes allosterically activate Toll-like receptor 9 Eicke Latz, Anjali Verma, Alberto Visintin et al. · Nature Immunology	17 Jun 2007	464
30	Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors Matthew Hiram Taylor, Chung‐Han Lee, Vicky Makker et al. · Journal of Clinical Oncology Open access	21 Jan 2020	459
31	Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial Josep Maria Llovet et al. · The Lancet Oncology Open access209 authors	28 Nov 2023	455
32	Applications of single-cell RNA sequencing in drug discovery and development Bram Van de Sande, Joon Sang Lee, Euphemia Mutasa-Gottgens et al. · Nature Reviews Drug Discovery ReviewOpen access	28 Apr 2023	455
33	Randomized phase III study 306 Gregory L. Krauss et al. · Neurology 125 authors	19 Apr 2012	433
34	Evaluation of adjunctive perampanel in patients with refractory partial‐onset seizures: Results of randomized global phase III study 305 Jacqueline A. French, Gregory L. Krauss, Bernhard Jochen Steinhoff et al. · Epilepsia	20 Aug 2012	429
35	The TLR4 antagonist Eritoran protects mice from lethal influenza infection Kari Ann Shirey, Wendy Lai, Alison J. Scott et al. · Nature Open access	May 2013	424
36	Comparison of Lemborexant With Placebo and Zolpidem Tartrate Extended Release for the Treatment of Older Adults With Insomnia Disorder Russell P. Rosenberg, Patricia Murphy, Gary K Zammit et al. · JAMA Network Open Open access	27 Dec 2019	414
37	Selective degradation of splicing factor CAPERα by anticancer sulfonamides Taisuke Uehara, Yukinori Minoshima, Koji Sagane et al. · Nature Chemical Biology	24 Apr 2017	404
38	Neuropsychiatric signs and symptoms of Alzheimer's disease: New treatment paradigms Krista L. Lanctôt, Joan C. Amatniek, Sonia Ancoli‐Israel et al. · Alzheimer s & Dementia Translational Research & Clinical Interventions Open access	5 Aug 2017	403
39	Amyloid-related imaging abnormalities (ARIA): radiological, biological and clinical characteristics Harald Juergen Hampel, Aya Elhage, Min Cho et al. · Brain Open access	6 Jun 2023	398
40	Physiologically Based Pharmacokinetic Model Qualification and Reporting Procedures for Regulatory Submissions: A Consortium Perspective Mohamad Shebley et al. · Clinical Pharmacology & Therapeutics Open access	10 Jan 2018	390
41	Circulating miRNA Biomarkers for Alzheimer's Disease Pavan Kumar, Zoltán Dezső, Crystal MacKenzie et al. · PLoS ONE Open access	29 Jul 2013	387
42	Direct Demonstration of Geranylgeranylation and Farnesylation of Ki-Ras in Vivo Cheryl A. Rowell, James J. Kowalczyk, Michael D. Lewis et al. · Journal of Biological Chemistry Open access	May 1997	371
43	A Randomized, Double‐Blind, Placebo‐Controlled Study of the Efficacy and Safety of Donepezil in Patients with Alzheimer's Disease in the Nursing Home Setting Pierre N. Tariot, Jeffrey L. Cummings, Ira R. Katz et al. · Journal of the American Geriatrics Society	Dec 2001	370
44	Cholinesterase Inhibitors Used in the Treatment of Alzheimer???s Disease David G. Wilkinson, Paul T. Francis, Elias M. Schwam et al. · Drugs & Aging	2004	367
45	Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial–mesenchymal transition (EMT) to mesenchymal–epithelial transition (MET) states Takeshi Yoshida, Yoichi Ozawa, Takayuki Kimura et al. · British Journal of Cancer Open access	25 Feb 2014	363
46	2014 Update of the Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception Michael Walter Weiner, Dallas P. Veitch, Paul S. S. Aisen et al. · Alzheimer s & Dementia Open access	Jun 2015	352
47	Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1‐6 hepatocellular carcinoma model Takayuki Kimura, Yu Kato, Yoichi Ozawa et al. · Cancer Science Open access	16 Nov 2018	350
48	Perampanel for tonic-clonic seizures in idiopathic generalized epilepsy Jacqueline A. French, Gregory L. Krauss, Robert T. Wechsler et al. · Neurology Open access	22 Aug 2015	332
49	Lemborexant, A Dual Orexin Receptor Antagonist (DORA) for the Treatment of Insomnia Disorder: Results From a Bayesian, Adaptive, Randomized, Double-Blind, Placebo-Controlled Study Patricia Murphy, Margaret L. Moline, David W. Mayleben et al. · Journal of Clinical Sleep Medicine Open access	15 Nov 2017	329
50	Developing the ATX(N) classification for use across the Alzheimer disease continuum Harald Juergen Hampel, Jeffrey L. Cummings, Kaj Blennow et al. · Nature Reviews Neurology Review	8 Jul 2021	328

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.